Journal Reviews

Allergy journal cover image.

Biologicals for severe chronic rhinosinusitis with nasal polyps. Any use?

5 November 2021 | | ENTA-Rhinology / Sinus | chronic rhinosinusitis, dupilumab, mepolizumab, omalizumab, reslizumab

Recent advances and knowledge of inflammatory endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP) led to introduction of biological agents such as monoclonal antibodies targeting IgE (omalizumab) and Interleukins (ILs) such as IL4R alpha (dupilumab) and IL5. The European Academy...

American Journal of Rhinology & Allergy cover image.

Can we predict how much benefit patients will get from ESS with a novel monoclonal antibody

1 July 2021 | | ENTA-Rhinology / Sinus | MLK, SNOT-22, allergic fungal rhinosinusitis, anti-IL-5, asthma, eosinophils, mepolizuma, nucala, prednisone rescue, recalcitrant

Mepolizumab (Nucala) is a humanised IgG1 monoclonal antibody that acts as an IL-5 antagonist. It has been shown to be highly effective in treating severe asthma. It is hypothesised that it will be effective for patients with recalcitrant CRSwNP. This...